Olav Hellebo was appointed as Chief Executive Officer in September 2014.
A highly experienced, international pharmaceutical executive he has broad commercial experience gained at both major pharmaceutical and small biotechnology companies. He has particular experience of the clinical development, out-licensing, commercialisation and marketing of new therapeutics.
Prior to ReNeuron, Olav held the role of CEO at Clavis Pharma ASA, a Norwegian, oncology focused, listed biotechnology company. At Clavis, Olav built a multi-national leadership team, taking the company’s lead programme through Phase III clinical development as well as completing substantial fundraising and out-licensing transactions for the business. Prior to Clavis, Olav headed up the global biologics franchise at UCB Pharma and was head of the UK commercial operations of Novartis.
Olav started his pharmaceutical career in 1992 at Schering-Plough, where he held a number of senior commercial roles in Europe and the US, including leading its US commercial operations in the areas of oncology, cardiovascular and hepatitis-C, representing annual sales in excess of $2 billion. Olav has an MBA from the IESE Business School in Spain and a Bachelor of Business Administration from Hofstra University, USA.
Michael Hunt joined ReNeuron in 2001. Between 2005 and 2014 he served as its CEO, leading the business through its early development to its current position as one of the global, clinical-stage leaders in the regenerative medicine field. He was appointed Chief Financial Officer in 2014.
He is a founding member and co-chair of the European Section of the US-based Alliance for Regenerative Medicine (ARM) and is a main board member of ARM. He also sits on the UK BioIndustry Association’s Cell & Gene Therapy Advisory Committee and its Finance and Tax Advisory Committee. He is currently a member of the Cell & Gene Therapy Catapult’s Advisory Panel.
Prior to ReNeuron, he spent six years at Biocompatibles International plc (sold to BTG plc) where he held a number of senior financial and general management positions. His early industrial career was spent at Bunzl plc. He read economics at University College London and qualified as a chartered accountant with Ernst & Young.
Dr Richard Beckman was appointed Chief Medical Officer in April 2018.
Prior to joining ReNeuron, Dr Beckman was the Chief Medical Officer of several innovative biotech and device firms, including Clearside, Ophthotech and Neurotech. Prior to that, he had leadership roles at Alcon, Lux Bio, Becton Dickinson and Allergan.
Dr Beckman received his MD from the University of Michigan, completed a residency in ophthalmology at Henry Ford Hospital, and a glaucoma fellowship at the Mass. Eye and Ear Infirmary/Harvard University. Prior to joining the industry, he practised in academic medicine for three years at Cornell University Medical College and was in private practice for 10 years.
Dr Randolph Corteling was appointed Head of Research in April 2015 having been a senior member of the research team since 2007.
Prior to joining ReNeuron, Dr Corteling started his scientific career as a Research Associate at Novartis, before undertaking a PhD in Medical and Surgical Sciences at The University of Nottingham. He then spent 3 years in Canada as a Heart and Stroke Foundation Fellow before joining ReNeuron in 2007. During his career, Dr Corteling has developed a number of new discoveries along with a thorough understanding of cell and stem cell biology with a particular interest and expertise in the role of extracellular vesicles and exosomes.
After his PhD, he spent three years as a Heart and Stroke Foundation postdoctoral fellow at the University of Calgary, Canada.
Sharon Grimster joined ReNeuron in 2013 and was subsequently appointed as VP Development & General Manager, Wales in April 2015.
She has significant experience in pharmaceutical development, and she has a particular expertise in biologics manufacturing.
Prior to working at ReNeuron, she held senior team roles at F-star and Antisoma, where she was responsible for a range of development functions, including project management, regulatory affairs, manufacturing, quality and business operations. Sharon started her pharmaceutical career at Celltech, where she led teams in project management, manufacturing and research.
Sharon recently qualified as a coach at the Henley Business School and has a B.Sc. from the University of Leicester and a Diploma in Management Studies. She is also an active member of a number of significant industry committees.
Dr Sinden is a scientific co-founder of ReNeuron and from 1998 to 2015 was an executive director of the ReNeuron companies.
Prior to founding ReNeuron and becoming its first employee, he was Reader in Neurobiology of Behaviour at the Institute of Psychiatry at Kings College London. He graduated in Psychology from the University of Sydney and completed a Ph.D. in Neuroscience from the Université Pierre et Marie Curie at the Collėge de France. He subsequently held post-doctoral appointments at Oxford University and the Institute of Psychiatry prior to joining the permanent staff of the Institute in 1987. He holds honorary professorships at the University College London School of Pharmacy and has over 140 scientific publications and book chapters.
He holds Fellowships of the Royal Society of Medicine and the Royal Society of Biology
Shaun Stapleton was appointed Head of Regulatory Affairs in June 2015.
He joined ReNeuron from RRG (a Voisin Consulting Life Sciences Company) where he was a Director and Vice President of Regulatory Science. He supported clients on a number of global development and registration projects, including advanced therapies and orphan drugs. Having graduated in Biochemistry from Imperial College, London, he began his career in research with the Imperial Cancer Research Fund, before moving into the pharmaceutical industry. He held positions of increasing responsibility in regulatory affairs at Sterling Winthrop, Eli Lilly and Boehringer Ingelheim before becoming Senior Director of Regulatory Affairs at Ipsen, where he managed regulatory input into development programmes globally, securing new product approvals in the US, EU and internationally in the neurology, endocrinology and oncology therapeutic areas.